Stockwinners Market Radar for December 29, 2022 - Earnings, Upgrades downgrades, option trades, Best Stock Advisory Service

20:09 EST Cathie Wood's ARK Investment bought 137K shares of DraftKings today

20:08 EST Cathie Wood's ARK Investment bought 70K shares of Roku today

20:07 EST Cathie Wood's ARK Investment bought 57K shares of Zoom Video today

20:06 EST Cathie Wood's ARK Investment bought 3.7M shares of Ginkgo Bioworks today

18:56 EST BeiGene CEO sells $2.16M in common stock - In a regulatory filing, BeiGene disclosed that its CEO John Oyler sold 9.6K shares of common stock on December 27 in a total transaction size of $2.16M.

17:21 EST B2Gold informs two employees passed away from injuries from robbery incident - B2Gold said in a statement that it "deeply regrets to report that two B2Gold employees have passed away as a result of injuries sustained in an off-site robbery incident in Mali earlier . All reports have identified this tragic event as the result of a robbery incident and not related to any terrorist activity. B2Gold wants to first and foremost express its deepest condolences to the families of the deceased employees. Our immediate concerns are for the safety and well-being of the B2Gold employees and the public and to minimise the impact on the surrounding area. Mining and processing activities at the Fekola Mine remain unaffected.

17:14 EST Masonite to incur $15M-$20M costs as part of restructuring plan - In a regulatory filing, the company states: "On December 27, 2022, Masonite International approved a plan intended to (i) better align its organizational structure and its long-term business strategy and (ii) continue to drive cost efficiencies through an optimized manufacturing footprint. This plan includes commencing certain restructuring actions across the Company's North American Residential and Architectural segments. The Company expects to incur pre-tax restructuring and other closure costs of $15.0 to $20.0 million related to the 2022 Restructuring Plan beginning in the fourth quarter of 2022 and continuing through fiscal year 2023, of which approximately 65% will be cash expenditures. The 2022 Restructuring Plan is intended to help improve the Company's profitability and cash flows once fully implemented. The Company expects to complete these actions by the end of fiscal year 2023 and to realize annual cash savings of approximately $15.0 to $20.0 million thereafter. The above costs are estimates and the actual costs may vary significantly based on various factors."

16:53 EST CFO of Dropbox Regan sells 3,000 shares of company stock - The CFO of Dropbox Timothy Regan disclosed in a regulatory filing that he had sold 3,000 shares of company stock at $22.30 per share on December 27 for a total transaction amount of $66,901.

16:44 EST Crowdstrike director Austin buys $2.5M in company shares - Crowdstrike director Roxanne Austin disclosed in a regulatory filing that she had purchased 25,000 shares of company stock at $99.74 per share between December 27 and December 28, for a total transaction amount of $2,493,500.

16:34 EST Heidrick & Struggles to acquire Atreus, terms undisclosed - Heidrick & Struggles has entered into an agreement to acquire Atreus. The acquisition builds on Heidrick & Struggles' leadership position in the on-demand talent space by expanding this offering into Continental Europe and is an important component of the firm's broader strategy to diversify its suite of executive talent and leadership advisory offerings. "We are seeing a transformation in how organizations are acquiring executive level talent and the expertise they need," said Dan Ryan, Managing Partner, On-Demand Talent, Heidrick & Struggles. "Having access to top talent to fill roles on an interim basis, or to drive major projects forward, is becoming an increasingly important solution for our clients. The acquisition of Atreus will strengthen our already market leading On-Demand Talent platform and extend Heidrick & Struggles' reach in this growing talent market segment, further underscoring our commitment to be at the forefront of delivering an integrated suite of executive talent and leadership advisory solutions." Heidrick & Struggles will acquire 100% of Atreus subject to the satisfaction or waiver of customary closing conditions, including obtaining applicable regulatory approvals. The acquisition is expected to occur early in the first quarter of 2023. Atreus generated annual revenue of approximately $61M in 2021 and will become part of Heidrick & Struggles' existing on-demand talent offering that includes US-based Business Talent Group BTG , acquired in 2021. Atreus will continue to be led by Co-CEOs, Dr. Harald Linne and Rainer Nagel, and operate as a wholly owned subsidiary of Heidrick & Struggles. Financial terms of the acquisition were not disclosed.

16:18 EST Bluebird Bio completes sale pf PRV to Argenx - Following the expiration of the applicable waiting period under the Hart-Scott-Rodino Antitrust Improvements Act of 1976, as amended, on December 29, bluebird bio completed the sale of a Rare Pediatric Disease Priority Review Voucher or PRV to Argenx . The Company was awarded the PRV under a U.S. Food and Drug Administration program intended to encourage the development of certain rare pediatric disease product applications. The Company received the PRV when SKYSONA or elivaldogene autotemcel, received accelerated approval by the FDA to slow the progression of neurological dysfunction in boys 4-17 years of age with early, active cerebral adrenoleukodystrophy. The Asset Sale was pursuant to the terms of an Asset Purchase Agreement, dated November 29 , the material terms of which were previously disclosed by the Company in a Current Report on Form 8-K filed with the Securities and Exchange Commission on November 30 . Pursuant to the PRV Transfer Agreement, Buyer paid the Company $102M in cash upon the closing of the Asset Sale.

16:13 EST AMC Entertainment elects Clark and Putnam to board, Wittlinger steps down - AMC Entertainment announced that the company's board of directors has elected Denise "Dee" Clark and Keri Putnam to the AMC Board of Directors, effective January 1, 2023. "They will each serve as a Class III director of the Company with a term expiring at the Company's 2023 Annual Meeting of Stockholders, and at that meeting will stand for re-election thereafter. Separately, Lee Wittlinger, a Managing Director at leading private investment firm Silver Lake, has served as an AMC Director since 2018 and will resign from his Board role at year end as is the general practice following Silver Lake's exit from an investment. Silver Lake sold its equity stake in AMC in January of 2021. With the appointments of Ms. Clark and Ms. Putnam, along with Mr. Wittlinger's resignation, AMC has made significant progress in reaching its diversity goals, given that three of AMC's nine Directors will be female, versus one of eight currently," the company stated.

16:02 EST Enovix appoints Raj Talluri as CEO - Enovix Corporation (ENVX) announced the appointment of Dr. Raj Talluri as president and CEO, effective January 18, 2023. Talluri is also expected to be appointed to the Enovix board of directors on a later date. Talluri joins Enovix from Micron Technology (MU), where he served as senior VP and General Manager of its Mobile Business Unit. Talluri replaces CEO and co-founder Harrold Rust, who is retiring from his position and the board but will serve in an advisory capacity to support the leadership transition.

15:24 EST High Tide closes acquisition of Jimmy's Cannabis Shop BC - High Tide announced the company has completed its acquisition of 100% of the equity interest of 1171882 B.C. Ltd., operating as Jimmy's Cannabis Shop BC, resulting in High Tide's acquisition of two retail cannabis stores currently operated by Jimmy's in British Columbia for $5.3M. The closing of the transaction brings High Tide's nationwide store count to 149, including six in British Columbia. The company also anticipates the organic opening of its location in Kamloops, BC, imminently. High Tide acquired 100% of Jimmy's for 2,595,533 common shares of High Tide valued at $5.3M, on the basis of a deemed price of C$2.0365 per High Tide share. The purchase price is subject to a post-closing working capital adjustment provision, to address any increase or decrease of working capital, inventory or cash estimated as of the closing date. The closing of the transaction remains subject to final approval from the TSX Venture Exchange. Pursuant to the acquisition agreement, 70% of the High Tide shares issued are subject to a four month hold.

14:50 EST Retractable Technologies trading halted, news pending

14:35 EST Kala Pharmaceuticals trading resumes

14:08 EST Justice Department files civil complaint against AmerisourceBergen over opioids - In a civil complaint filed today, the Department of Justice alleges AmerisourceBergen violated federal law in connection with the distribution of controlled substances to pharmacies and other customers across the country, contributing to the prescription opioid epidemic. The complaint alleges that this unlawful conduct resulted in at least hundreds of thousands of violations of the Controlled Substances Act. The Justice Department seeks civil penalties and injunctive relief. The government's complaint alleges that for years AmerisourceBergen flouted its legal obligations and prioritized profits over the well-being of Americans. If AmerisourceBergen is found liable, it could face escalating civil penalties depending on when each violation occurred and the type of controlled substance at issue, specifically, up to $10,000 for each reporting violation before November 2015, up to $16,864 for each violation between November 2015 and October 2018 and for each violation relating to a suspicious order for a non-opioid controlled substance not reported after October 2018, and up to $109,374 for each violation relating to a suspicious opioid order not reported after October 2018, potentially totaling billions of dollars in penalties, the Justice Department said in a statement. Reference Link

13:49 EST Vericel announces FDA approval of NexoBrid for severe thermal burns - Vericel (VCEL) announced that the U.S. Food and Drug Administration has approved NexoBrid for the removal of eschar in adults with deep partial-thickness and/or full-thickness thermal burns. The FDA approval of NexoBrid is based on multiple preclinical and clinical studies, including the pivotal Phase 3 U.S. clinical study which evaluated NexoBrid in adult patients with deep partial-thickness and full-thickness thermal burns of 3%-30% of total body surface area. The study met its primary endpoint of complete eschar removal as well as all secondary endpoints, including shorter time to eschar removal and a lower incidence of surgical eschar removal compared to standard of care, including both surgical and non-surgical eschar removal methods. A key safety endpoint, non-inferiority in time to greater than95% wound closure compared with patients treated with SOC, was also achieved. NexoBrid is a registered trademark of MediWound (MDWD) and is used under license to Vericel Corporation

13:37 EST SeaStar Medical, Nuwellis announce exclusive U.S. license and distribution pact - SeaStar Medical (ICU) and Nuwellis (NUWE) announce an exclusive U.S. license and distribution agreement by Nuwellis of SeaStar Medical's Selective Cytopheretic Device, or SCD, for the treatment of acute kidney injury in children. Nuwellis will market and distribute the SCD through its direct salesforce to nephrologists and intensive care physicians who are trained in pediatric extracorporeal therapy. SeaStar Medical expects the U.S. Food and Drug Administration to complete a substantive review of a Humanitarian Device Exemption for the use of SCD in children with AKI during the first quarter of 2023, with a potential commercial introduction in the second quarter of 2023, the companies stated. "Nuwellis' established relationships with pediatric nephrology and intensive care key opinion leaders make them the ideal marketing partner for SCD in this indication. With Nuwellis, we have a proven, efficient means to reach our target customers while allowing SeaStar Medical to advance additional indications including a planned pivotal clinical trial in the adult acute kidney injury population, which we expect to initiate during the first quarter of 2023," said Eric Schlorff, CEO of SeaStar Medical.

13:11 EST Biogen responds to Committee on Oversight, stands by 'integrity' of actions - Biogen issued the following corporate statement on the House Committee on Oversight report: "Since 2021 Biogen has been working cooperatively with the U.S. House Committee on Oversight and Reform and the U.S. House Energy and Commerce Committee regarding their investigations into the launch of Aduhelm, including providing requested information... Biogen has been committed to researching and developing treatments for Alzheimer's disease for more than a decade. We have been focused relentlessly on innovation to address this global health challenge, and have adapted to both successes and setbacks. Biogen stands by the integrity of the actions we have taken. As stated in the congressional report, an FDA review concluded that, 'There is no evidence that these interactions with the sponsor in advance of filing were anything but appropriate in this situation.' Alzheimer's is a highly complex disease and we have learned from the development and launch of Aduhelm. That process is continuing to inform our work as Biogen introduces new innovative treatments to the market. We will continue to appropriately engage diverse stakeholders at every step, including patients and their families, health care providers, and the scientific community. We are dedicated to our mission of bringing innovative and transformative treatments to patients with serious and hard-to-treat conditions." Reference Link

12:00 EST Direxion Daily Semiconductor Bear 3X Shares falls -9.5% - Direxion Daily Semiconductor Bear 3X Shares is down -9.5%, or -$4.14 to $39.46.

12:00 EST Blue Earth falls -22.9% - Blue Earth is down -22.9%, or -$2.40 to $8.08.

12:00 EST Carvana rises 15.9% - Carvana is up 15.9%, or 61c to $4.44.

11:38 EST Beyond Meat rises after McDonald's UK&I announces 'Double McPlant' - McDonald's UK&I (MCD) announced earlier the launch of the Double McPlant in all UK & Ireland restaurants from Wednesday January 4, "just in time for those taking part in Veganuary or those who just simply crave a tasty new burger from McDonalds." The company stated: "The undeniably delicious McPlant, which took over three years to develop, features a patty co-created with Beyond Meat and has already proved wildly successful with customers since its launch in September 2021. It's no secret that people went wild for the taste, with many taking to Twitter to express their desire for a doubled-up version." In Thursday morning trading following the launch announcement, shares of Beyond Meat (BYND) are up $1.49, or 13%, to $12.84. Reference Link

10:59 EST ReShape Lifesciences Inc trading halted, volatility trading pause

10:00 EST New Oriental Education falls -10.2% - New Oriental Education is down -10.2%, or -$3.72 to $32.65.

10:00 EST Lightspeed rises 7.8% - Lightspeed is up 7.8%, or $1.00 to $13.75.

10:00 EST FiscalNote rises 10.4% - FiscalNote is up 10.4%, or 56c to $5.94.

09:47 EST New Oriental Education falls -12.0% - New Oriental Education is down -12.0%, or -$4.37 to $32.00.

09:47 EST RXO Inc. rises 5.4% - RXO Inc. is up 5.4%, or 88c to $17.20.

09:47 EST ProShares UltraShort Bloomberg Natural Gas rises 6.5% - ProShares UltraShort Bloomberg Natural Gas is up 6.5%, or $1.65 to $27.00.

09:41 EST Relativity Acquisition Corp trading resumes

09:37 EST Nuwellis Inc trading resumes

09:33 EST Nevada reports November statewide gaming win down 7.62% to $1.22B - Reports Las Vegas Strip gaming win down 11.33% versus last year to $669.48M. Publicly traded companies in the gambling space space include Boyd Gaming (BYD), Caesars (CZR), Churchill Downs (CHDN), DraftKings (DKNG), Flutter Entertainment (PDYPY), Gan Limited (GAN), Las Vegas Sands (LVS), MGM Resorts (MGM), Penn Entertainment (PENN), William Hill (WIMHY) and Wynn Resorts (WYNN).

09:32 EST Nuwellis Inc trading halted, volatility trading pause

09:31 EST Frequency Electronics trading halted, volatility trading pause

09:21 EST AerCap delivers first of six new Airbus A330neo Aircraft to Condor - AerCap (AER) announced the delivery of the first of six new Airbus (EADSY) A330-900neo aircraft to German leisure carrier, Condor. The remaining aircraft are scheduled to deliver in summer 2023 through 2024. "We are delighted to announce the delivery of the first of six new Airbus A330-900neo aircraft to Condor, and to see the aircraft painted in their distinctive new striped livery design," said Peter Anderson, the Chief Commercial Officer of AerCap. "The A330neo aircraft is the perfect choice for Condor and will enable them to expand their network using the most modern, fuel-efficient technology while supporting their sustainability commitments. We wish the team every success and we look forward to continuing to build our partnership in the years to come."

09:11 EST Lexaria Bioscience receives patent in Canada - Lexaria Bioscience announced its continued accumulation of international patent recognition with the receipt of its first granted patent in Canada, which is its 28th granted patent worldwide. Canadian Patent #3,093,414 is the first granted patent from Lexaria's sixth patent family and is entitled "Transdermal And/Or Dermal Delivery Of Lipophilic Active Agents". The patent is for improved compositions and methods for transdermal and dermal delivery of cannabinoids, including cannabidiol and tetrahydrocannabinol. Similar patent applications for skin-based delivery of DehydraTECH formulations remain pending in many other countries.

09:09 EST Outlook Therapeutics sees funding through FDA approval of ONS-5010 - At September 30, 2022, Outlook Therapeutics had cash and cash equivalents of $17.4 million. Subsequent to September 30, 2022, the Company closed a registered direct equity offering priced at-the-market under Nasdaq rules, resulting in aggregate gross proceeds of approximately $25.0 million. Additionally, the Company closed on an unsecured convertible promissory note with a face amount of $31.8 million and net proceeds of approximately $30.0 million after original issue discount and after deducting the Lender's transaction costs covered by the Company in connection with the issuance. The combined proceeds from the Note and the registered direct offering are expected to provide funding through the anticipated FDA approval of ONS-5010 in the third calendar quarter of 2023.

09:08 EST Outlook Therapeutics announces anticipated milestones - Continued progress with ongoing pre-launch commercial preparations in anticipation of potential approval for ONS-5010 in 2023; PDUFA goal date of August 29, 2023; and Estimated decision date from the EMA's Committee for Medicinal Products for Human Use on the Company's submitted MAA in EU for ONS-5010 expected in early 2024.

09:05 EST Kaiser Aluminum publishes 2021 sustainability report - Kaiser Aluminum published its 2021 Sustainability Report summarizing the Company's focus and initiatives around its environmental, social and governance programming and development as it continues to manage its business for long-term success in a manner that is economically, environmentally and socially responsible. Highlights of the Company's 2021 Sustainability Report: Expanded environmental disclosures to include operational metrics for our Warrick rolling mill, water program case studies for our Trentwood rolling mill, waste information and sustainability goals and highlights focused on greenhouse gas emissions intensity, reduction goals, plans and progress. Expanded the scope of duties and responsibilities of our Board's ESG Committee to provide more focused oversight of the Company's ESG activities and strategic initiatives. Enhanced social disclosures focused on cybersecurity, the Kaiser Aluminum Women's Leadership Program and a link to the Company's Equal Employment Opportunity report. Reported strong 2021 safety performance with a record lost-time case incident rate, representing a 30% reduction compared to 2020. Provided updated governance highlights supporting Board composition best practices and updated supply chain data. Provided additional metrics and enhanced disclosures based upon the Sustainability Accounting Standards Board with the objective over time of more fully aligning with SASB and the Task Force on Climate-Related Financial Disclosures.

09:02 EST Alibaba names new CTO as CEO steps in interim cloud head - Alibaba Group unveiled senior management changes on Thursday, including Wu Zeming's rise to the platform company's C-suite as CTO. In a separate move, Jeff Zhang will focus on his role as head of the Alibaba DAMO Academy and no longer serve as President of Alibaba Cloud Intelligence. Jeff will continue to be responsible for Alibaba's proprietary chip development team T-Head and Internet of Things initiatives. In Jeff's stead, Daniel Zhang, Chairman and CEO of Alibaba Group, will assume the role of acting President of Alibaba Cloud Intelligence and responsibility for the communication and collaboration platform DingTalk. Alibaba regularly reshuffles management annually to keep pace with the evolving internet space and with the growth of the team. Wu Zeming succeeds Li Cheng as CTO. After joining Alibaba in 2002, he made partner at Alibaba in 2017. Before Cheng became Alibaba's CTO in 2019, he held various senior roles at its financial services affiliate, Ant Group. Moving forward, Cheng will continue to work with Daniel Zhang as an advisor on technology. Zhou Jingren will serve as CTO of Alibaba Cloud Intelligence in addition to his current role as Deputy Head of the DAMO Academy. On April 1, 2023, Jane Jiang will succeed Judy Tong as Group Chief People Officer, a role she has held since 2017. One of Alibaba's 18 original co-founders, Jiang is a senior executive in the company's human resources team, responsible for personnel management, including the safety, community-building and satisfaction of employees.

08:51 EST KULR Technology partners with Theory Racing to develop e-bike batteries - KULR Technology Group announced a partnership with Theory Racing. The partnership with Theory comes on the heels of the Company announcing that it will introduce its all-new modular energy storage platform, KULR ONE, at CES 2023 this January 5-8. KULR ONE is a family of next-generation battery packs bringing a combination of safety, performance, intelligence, modularity and reliability to the world's most demanding applications.

08:47 EST Hoth Therapeutics announces FDA acceptance of IND application for HT-001 - Hoth Therapeutics announced that the U.S. Food and Drug Administration, FDA, has accepted an Investigational New Drug, IND, application for the company's HT-001 therapeutic for the treatment for rash and skin disorders associated with epidermal growth factor receptor, EGFR, inhibitor therapy. "We are excited to begin our trial and bring hope to patients who are suffering. With no specific treatment currently approved for the treatment of skin toxicities associated with EGFRi therapies, this trial brings us one step closer to a new treatment option for underserved cancer patients," said Robb Knie, CEO of Hoth Therapeutics, Inc. "We look forward to advancing HT-001 into the clinical phase as we believe that this novel therapeutic will be a key treatment in the onco-dermatology space. We anticipate beginning our Phase 2a trial in Q1 of 2023."

08:43 EST Calumet Specialty Products provides 2022 year end operational update - Calumet Specialty Products Partners provided a year-end operational update, including a project and business update at Montana Renewables and company-wide impact from the December arctic blast. Montana Renewables and Montana Refining: Separation of Montana Renewables and the Great Falls Specialty Asphalt refinery was completed during the fourth quarter with both businesses operating in their new services. The 12,000 bpd specialty asphalt refinery is presently running at nameplate capacity on Canadian heavy crude. Montana Renewables commissioned its modified hydrocracker in renewable diesel service on November 5, then retrofitted additional winterization capability during the month of November. Catalyst performance has been consistent and met the expected performance envelope provided by Haldor Topsoe. The current 6,000 bpd capacity will increase to 12,000 bpd with the sequential commissioning of renewable hydrogen, SAF, and feedstock pre-treater which are expected online in that order in 1Q2023. Specialties Business: Calumet's specialty business has performed exceptionally well in 2022, including throughput and profitability records across the system and at most individual plants. This performance was supported by exceptional execution of key turnarounds in Shreveport and Princeton and capital investments targeting reliability and deeper integration between assets, widening a key competitive advantage of this business. Last week, Calumet's production was impacted with nearly all units being either circulated or shutdown during the extreme weather event. Since then, city water has been restored, and the company is currently in startup. All other plants are back up in production. Demand in the specialty business continues to be healthy considering routine seasonal volume patterns. The company sees typical soft winter asphalt margins and continue to experience strong specialty product margins as the company enters 2023.

08:42 EST 180 Life Sciences CEO says priorities continue to be clinical programs - The company said, "As we come to the end of 2022, I am pleased to provide an update for our shareholders. In keeping with good corporate practice and US Securities and Exchange Commission regulations, we have refrained from answering individual queries from shareholders until we were able to provide information to all shareholders at the same time. Our priorities continue to be our clinical programs, repurposing anti-Tumor Necrosis Factor drugs for treating Dupuytren's disease, frozen shoulder and post-operative delirium. The Dupuytren's contracture trial phase 2B trial, led by Prof Nanchahal, the results of which we have previously announced, exceeded our expectations. It also showed that the treatment is likely to be cost-effective. Now, after obtaining scientific advice from the UK Medicines and Healthcare products Regulatory Agency, the UK equivalent of the US Food and Drug Administration, and after discussions with our regulatory consultants in the United States and United Kingdom, we made the decision to begin preparing all the material necessary to seek marketing authorization in the UK. Based on the guidance received from our regulatory consultants on the time required to prepare the marketing authorization application, we currently plan on filing the application in mid-2023. In seeking a marketing authorization, we plan to engage a specialized consultant, Dr. Keith Watson, who spent nearly five years with the MHRA as a reviewer of biologics product applications, later serving as Director of Global Regulatory Affairs, Biologics Strategic Development Group at AbbVie, and more recently Vice President of Regulatory Affairs for Celltrion Inc. He now manages his own regulatory consulting practice....A published study from the Netherlands showed that increase in nodule size correlates with finger flexion deformity and we reason that a reduction in nodule size would conversely mean that fingers are less likely to contract. As previously disclosed, the MHRA reviewed the primary and secondary endpoints in the phase 2b trial and the data provided by the Company and noted that it has not been shown that reducing nodule size via treatment would lead to improvements in terms of Dupuytren's disease progression. We plan to continue to collect all available data to address the point made by the MHRA. In addition, we may conduct a follow-on study to address the requirements of the MHRA, the EU, and the US FDA. We expect Dr. Watson will provide us advice regarding the best path forward assuming we receive Conditional Marketing Authorization. With the recent financing complete, the Company is proceeding with the preparation of the necessary CMA application documents. It is a very substantial, but worthwhile task...Enrollment to the trial of anti-TNF for early-stage frozen shoulder is slower than anticipated in the UK as patients typically present to physical therapists and the processes are subject to delays. In the USA, all such patients are seen by orthopedic physicians, who are relatively easy to access. The trial team has implemented several strategies to improve recruitment and we hope that these will be effective. Preparation for the trial of anti-TNF to prevent the development of postoperative delirium remains on track and we anticipate that the first patient will be recruited in the first half of 2023...Our HMGB1 program continues to advance slowly. The molecular dynamics for the binding of this molecule are extremely complex and potentially need more extensive research in order to identify a lead candidate. The synthetic cannabinoid program is also moving along, albeit slower than expected, with an emphasis on more effective formulations to ensure that the cannabinoids are much more orally available, as they are currently very poorly absorbed. We are continuing with our research in this field towards the development of a treatment for chronic pain. Assuming that the oral formulation research efforts are successful, we may initiate early trials in patients suffering from chronic pain, perhaps in early 2024. As most of you know, we remain in some ongoing litigation and at this point we have no further update on such matters other than what has been reported in extensive detail in our most recent Quarterly Report on Form 10-Q."

08:39 EST Euroseas announces sale of 5,610 teu container vessel - Euroseas announced that it has agreed to sell M/V Akinada Bridge, a 5,610 teu intermediate containership vessel built in 2001, at a gross price of $14.2M. The vessel is expected to be delivered to its buyers in the beginning of January 2023.

08:37 EST HeartBeam sees HeartBeam AIMI to be cleared in Q1 time frame - HeartBeam issued a letter to shareholders from its Chief Executive Officer and Founder, Branislav Vajdic, PhD. 2022 was a transformative year for HeartBeam and for our technology and business, highlighted by ongoing advancements in our product launch timeline for the HeartBeam AIMIGo 12-Lead 3D Vector Electrocardiogram ECG Device and HeartBeam AIMI...Developed by our pioneering team, our HeartBeam AIMI and HeartBeam AIMIGo solutions will transform the way patients and doctors detect heart attacks. By providing remote, 12-lead 3D vector ECG VECG capability, the HeartBeam platform intends to offer fast, accurate detection of heart attacks and complex cardiac arrhythmias for the first time outside of a medical setting. We expect the HeartBeam AIMI system for use in acute care settings to receive regulatory approval in the near future. We are in discussions with the FDA and plan to meet with them soon and expect HeartBeam AIMI to be cleared in the Q1 2023 time frame ..We plan to focus in 2023 and 2024 on the expansion of our core technology features, the 3D VECG data and clinical studies that we believe will establish our platform as the standard of care for ambulatory-based cardiology and taking advantage of the comprehensiveness of our technology.

08:35 EST Bridgeline, Shopify partner for prescriptive marketing dashboard eCommerce360 - Bridgeline Digital (BLIN) announced that its prescriptive marketing dashboard, eCommerce360, is now available within the app store on the Shopify (SHOP) platform. Shopify has partnered with Bridgeline to power analytics and prescribe new revenue strategies for their base of more than 4 million users across 175 countries. Users now can integrate the Bridgeline eCommerce360 app to their Shopify sites and use the e360 dashboard directly within the Shopify admin interface.

08:08 EST Osisko Mining announces TSX approval to renew normal course issuer bid - Osisko Mining announces that the Toronto Stock Exchange has approved the Corporation's notice of intention to make a normal course issuer bid. Under the terms of the NCIB Program, Osisko may acquire up to 29,053,640 of its common shares from time to time in accordance with the normal course issuer bid procedures of the TSX. The normal course issuer bid will be conducted through the facilities of the TSX or alternative trading systems, if eligible, and will conform to their regulations. Purchases under the normal course issuer bid will be made by means of open market transactions or such other means as a securities regulatory authority may permit, including pre-arranged crosses, exempt offers and private agreements under an issuer bid exemption order issued by a securities regulatory authority. Repurchases under the NCIB Program may commence on January 2, 2023 and will terminate on January 1, 2024 or on such earlier date as the NCIB Program is complete. Daily purchases will be limited to 126,972 Common Shares, other than block purchase exemptions, representing 25% of the average daily trading volume of the Common Shares on the TSX for the six-month period ending November 30, 2022, being 507,890 Common Shares. The price that the Corporation may pay for any Common Shares purchased in the open market under the NCIB Program will be the prevailing market price at the time of purchase (plus any brokerage fees) and any Common Shares purchased by the Corporation will be cancelled. In the event that the Corporation purchases Common Shares by pre-arranged crosses, exempt offers, block purchases or private agreements, the purchase price of the Common Shares may be, and will be in the case of purchases by private agreements, as may be permitted by the securities regulatory authority, at a discount to the market price of the Common Shares at the time of acquisition.

08:04 EST ViaSat awarded five-year $325M IDIQ contract by U.S. SOCOM - Viasa announced it was awarded an indefinite delivery, indefinite quantity, IDIQ, contract award worth up to $325M over a five-year period to support the U.S. Special Operations Command, SOCOM. This sole-source IDIQ is an extension of a $350M IDIQ contract awarded to Viasat in 2017. Under the contract award, Viasat will continue to provide advanced mission equipment, services and support to sustain and improve situational awareness, integration, terrestrial networking, intelligence, surveillance and reconnaissance, tactical satellite communications, information assurance and network management capabilities of Special Operations Forces. "This contract award reaffirms Viasat's deep commitment and partnership with the SOCOM community to understand and address the capability needs of forces for the most complex missions," said Craig Miller, president of Viasat Government Systems. "Networking and communications needs across the modern battlespace are continually evolving and we're excited to help SOCOM maintain the advantage with solutions that deliver the performance, flexibility and resilience Special Operations Forces require to successfully operate independently and interoperate effectively with joint forces."

08:02 EST Transcode announces FDA authorization to proceed with first-in-human trial - TransCode Therapeutics announced that it has received written authorization from the U.S. Food and Drug Administration that it may proceed with its First-in-Human Phase 0 clinical trial. The planned clinical trial is to evaluate TransCode's lead therapeutic candidate, TTX-MC138, in up to 12 cancer patients with advanced solid tumors. TTX-MC138 is designed to inhibit the pro-metastatic RNA, microRNA-10b, described as the master regulator of metastasis in a number of advanced solid tumors. TransCode believes that TTX-MC138 could be used as a treatment for many of these cancers. The Company believes that TTX-MC138 has the potential to dramatically improve clinical outcomes in a range of cancers, including breast, pancreatic, ovarian and colon cancer, glioblastomas and others. In a preclinical murine model of triple-negative breast cancer model, treatment with low-dose chemotherapy and TTX-MC138 eliminated pre-existing local metastases in 100% of treated animals representative of stage II/III metastatic cancer. In a more aggressive murine model representative of stage IV metastatic cancer, treatment with low-dose chemotherapy and TTX-MC138 resulted in elimination of distant metastases in 65% of animals treated. In a murine model of pancreatic adenocarcinoma, administration of TTX-MC138 as monotherapy resulted in complete responses, manifested as regression without recurrence, in 40% of treated animals. In addition to murine models of cancer, TTX-MC138 was successfully delivered and demonstrated preliminary efficacy in a case study of spontaneous feline mammary carcinoma. A Phase 0 clinical trial is an exploratory study conducted under an Investigational New Drug application. In TransCode's planned clinical trial, up to 12 patients will be given a single dose of radiolabeled TTX-MC138 followed by noninvasive positron emission tomography-magnetic resonance imaging. The trial is intended to quantify the amount of radiolabeled TTX-MC138 delivered to metastatic lesions and the pharmacokinetics of the therapeutic candidate in cancer patients. The trial could yield critical data regarding therapeutic dose, timing, and potential safety that could inform later stage clinical trials. This trial is not intended to demonstrate any therapeutic effect.

07:40 EST Ardelyx up 9% in pre-market at $2.73 after FDA grants appeal for XPHOZAH

07:32 EST WeTrade enters strategic cooperation with Fujian Super Solar Energy Technology - WeTrade Group announced that the Company has entered into strategic cooperation with Fujian Super Solar Energy Technology, under which the two parties will work together to develop portable energy storage products and distribute them globally. Seeing the booming downstream application, the two groups will work together to meet the demand of market, and push the rapid growth in their respective business scale. This cooperation also marks the official entry of WeTrade Group into the new energy market. Hechun Wei, Chief Executive Officer of the Company, commented, "This entry into the new energy market has been a part of the company's strategy and an important step up in 2023. The entry will further consolidate the Company's market position, improve brand awareness and benefit shareholders."

07:08 EST Laser Photonics demonstrates CleanTech laser systems for soldiers - Laser Photonics recently provided a demonstration of two CleanTech laser systems for soldiers at the Anniston Army Depot in Anniston, AL. Soldiers at the Anniston Army Depot were introduced to two CleanTech handheld laser cleaning systems, the CleanTech 2000-CTH JobSite and the CleanTech LPC-300-CTH. The demonstration allowed soldiers on the base responsible for MRO to gain first-hand exposure to the benefits of LPC's CleanTech laser cleaning systems over abrasives and other cleaning processes, including safety, efficiency and environmental concerns.

07:06 EST Freight Technologies supports industrial electric motor manufacturer - Freight Technologies now supports cross-border logistics requirements for a global electric-electronic equipment company with eighteen different factories and distribution centers across the US and Mexico.

07:05 EST H-CYTE completes acquisition of SkinDisc from Scion Solutions - H-CYTE announced that the Company completed its acquisition of SkinDisc. Highlights: SkinDisc acquisition further diversifies H-CYTE's asset portfolio; Early clinical outcomes of SkinDisc application demonstrated significant results relative to current treatment options in wound healing and limb salvage; Currently in dialogue with the FDA and have a manufacturer established; Over 500 patients treated with SkinDisc to date; Single application can achieve healing in 4-9 weeks; H-CYTE will submit a De Novo 510(k) pathway request for SkinDisc in the first half of 2023; Equity proceeds funded the acquisition of SkinDisc. From a single application, SkinDisc provides an active cellular matrix that maintains complete full wound contact and depth fill during the healing process, resulting in rapid growth of the host tissue. The SkinDisc product achieves healing in four to nine weeks, compared to current treatment approaches that require weekly applications and can take 12-20 weeks to heal, on average.

07:02 EST AirNet Technology regains compliance with Nasdaq minimum bid price - AirNet Technology announced that it received a notification letter from the Listing Qualifications Department of The Nasdaq Stock Market on December 27, 2022, indicating that the Company has regained compliance with the minimum bid price requirement set forth in Rule 5550(a)(2) of the Nasdaq Listing Rules. According to the Notification Letter on Compliance, the staff of Nasdaq has determined that for the last 10 consecutive business days, from December 12, 2022 through December 23, 2022, the closing bid price of the Company's ADSs had been at $1.00 per ADS or greater, and the Company has regained compliance with Rule 5550(a)(2) of the Nasdaq Listing Rules.

06:58 EST Asensus Surgical announces Senhance program initiation at Kashiwa Kosei - Asensus Surgical announced that Kashiwa Kosei General Hospital in Kashiwa, Japan has entered into an agreement to lease and utilize a Senhance Surgical System.

06:51 EST Sitio Royalties, Brigham Minerals announces completion of merger - Sitio Royalties Corp. (STR) and Brigham Minerals (MNRL) announced the completion of their merger, combining as Sitio Royalties Corp. The company said, "The combination brings together two of the largest public companies in the mineral and royalty sector with complementary high-quality assets in the Permian Basin and other oil-focused regions, creating an industry leader with a proven track record of consolidating oil and gas mineral and royalty interests operated by a diverse set of E&P companies."

06:37 EST Nutriband to launch AI Tape brand in Q1 - Nutriband announced that it has begun production of its AI Tape brand with an expected launch of the product line in Q1 2023. AI Tape is designed to share many of the benefits of traditional Kinesiology Tape. AI Tape further adds soothing and therapeutic ingredients held in suspension with a proprietary adhesive mix. AI Tape is manufactured in the USA at the Company's Pocono Pharmaceutical facility in North Carolina.

06:31 EST Kingsoft Cloud announces results of extraordinary general meeting - Kingsoft Cloud Holdings announced that the shareholders of the Company duly adopted all the resolutions proposed by the Company at its extraordinary general meeting of shareholders held in Beijing today, with high approval rate, paving way to Company's proposed listing on Main Board of The Stock Exchange of Hong Kong Limited. Earlier on December 23, 2022, the Company announced the proposed dual primary listing of its ordinary shares, par value US$0.001 per share by way of introduction on the Main Board of The Stock Exchange of Hong Kong Limited. Subject to final listing approval from the SEHK, the Shares are expected to commence trading on the Main Board of the SEHK on December 30, 2022 under the stock code "3896". Upon listing on the Main Board of the SEHK, the Company's American Depositary Shares, each representing 15 Shares, will continue to be primarily listed and traded on The NASDAQ Global Select Market, and the Shares listed on the Main Board of the SEHK will be fully fungible with the ADSs listed on the NASDAQ. On the same day, the Company also announced the appointment of Mr. Haijian He, CFO, as a member of the Board of Directors and a member of the Corporate Governance Committee of the Board, effective on December 20, 2022. Resolution 1: As a Special Resolution: to amend and restate the existing Amended and Restated Memorandum of Association and Articles of Association of the Company by the deletion in their entirety and by the substitution in their place of the Second Amended and Restated Memorandum of Association and Articles of Association, conditional upon and with effect from the consummation of the Company's proposed listing on The Stock Exchange of Hong Kong. Resolution 2: As a Special Resolution: to change the name of the Company from Kingsoft Cloud Holdings Limited to Kingsoft Cloud Holdings Limited by adoption of the dual Chinese name , which will be reflected in the Proposed M&AA Amendment. Resolution 3: As an Ordinary Resolution: a general mandate be granted to the Directors to allot, issue or deal with additional shares of the Company not exceeding 20% of the total number of issued shares immediately following completion of the Listing, and which is conditional upon the Listing. Resolution 4: As an Ordinary Resolution: a general mandate be granted to the Directors to exercise powers of the Company to repurchase shares of the Company representing up to 10% of the total number of issued shares immediately following completion of the Listing, and which is conditional upon the Listing. Resolution 5: As an Ordinary Resolution: subject to an approval of the Issuance Mandate and the Repurchase Mandate and conditional upon the Listing, an extension to the Issuance Mandate be approved, such that the number of shares of the Company repurchased under the Repurchase Mandate will also be added to extend the Issuance Mandate, provided that such additional amount shall not exceed 10% of the number of issued shares of the Company immediately following completion of the Listing. Resolution 6: As an Ordinary Resolution: the authorization to each of the directors of the Company or the Company's registered office provider to take any and all action that might be necessary to effect the foregoing resolutions and make all necessary filings at the Cayman Registry as such director or the Company's registered office provider, in his, her or its absolute discretion, thinks fit.

06:06 EST Clearmind announces shareholders meeting results - Clearmind Medicine announced that all of the matters put forward before shareholders for consideration and approval at its meeting held on December 28, 2022, as set out in the Company's Management Information Circular dated November 28, 2022, were approved by the requisite majority of votes cast at the Meeting, including the approval of the Company's rolling stock option plan and an increase to the amount of options available for issuance thereunder, and an increase to the amount of restricted share units, and underlying common shares, available for issuance pursuant to the Company's Restricted Share Unit Plan.

06:04 EST Standard Lithium receives notice of allowance for U.S. patent on DLE process - Standard Lithium announced that the United States Patent and Trademark Office has issued a Notice of Allowance for Standard Lithium's third U.S. patent application serial no. 16/895,783 titled "Process for Recovering Lithium from Brines", This third U.S. patent application is in addition to Standard Lithium's other two U.S. patent applications for which Notices of Allowance have been earlier issued by the USPTO. These three U.S. patent applications comprise a portion of Standard Lithium's novel and proprietary technique for continuous Direct Lithium Extraction from lithium brines. A Notice of Allowance is issued by the USPTO after examination of a patent application and a determination that a patent should be granted from the application. Standard Lithium anticipates the issue of the formal registration of this third U.S. patent application in the coming months.

05:05 EST Standard Lithium issued third Notice of Allowance for brines from USPTO - Standard Lithium announced that the United States Patent and Trademark Office, or USPTO, has issued a Notice of Allowance for Standard Lithium's third U.S. patent application serial no. 16/895,783 titled "Process for Recovering Lithium from Brines", This third U.S. patent application is in addition to Standard Lithium's other two U.S. patent applications for which Notices of Allowance have been earlier issued by the USPTO. These three U.S. patent applications comprise a portion of Standard Lithium's novel and proprietary technique for continuous Direct Lithium Extraction, or DLE, from lithium brines.